Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ivonescimab (PD-1/VEGF Bispecpecial Antibody) in the Treatment of Multiple Advanced Tumors: a Multi-cohort, Multi-center, Single-arm Phase II Study

NCT06683846 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06683846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06683846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ivonescimab (PD-1/VEGF Bispecpecial Antibody) in the Treatment of Multiple Advanced Tumors: a Multi-cohort, Multi-center, Single-arm Phase II Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
November 20, 2024
Completion date
November 30, 2027
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adrenal cortical cancer, basal cell carcinomas, clear cell renal cancer, germ cell cancer metastatic, kidney cancer, neuroendocrine cancer, non-clear cell renal cell carcinoma, paget disease, extramammary, penile cancer, perivascular epithelioid cell tumor, malignant, pheochromocytoma/paraganglioma, prostate cancers, rare tumors, renal angiomyolipoma, rhabdomyosarcoma, sarcoma, sarcomatoid carcinoma, urachal cancer, urothelial carcinoma